Prelude Therapeutics Inc
PRLD0.851USD
+0.023+2.76%
交易中 （美东）报价延迟15分钟
48.05M总市值
亏损市盈率 TTM
关于 Prelude Therapeutics Inc 公司
Prelude Therapeutics Incorporated 是一家临床阶段的完全整合肿瘤学公司，以药物发现为基础，为医疗资源匮乏的患者提供新型精准抗癌药物。该公司开发了由多个不同项目组成的多样化产品线：激酶、靶向蛋白降解剂和精准抗体药物偶联物。其候选产品包括 PRT3789、PRT2527 和 PRT3645。PRT3789 是一种高度选择性的 SMARCA2 蛋白降解剂，与 SMARCA4 一起通过染色质重塑控制基因调控。其 CDK9 项目是癌症促进转录程序的重要调节器，包括由 MCL1、MYC 和 MYB 驱动的转录程序。PRT3645 是一种脑和组织渗透分子，可有效靶向 CDK4/6，对 CDK4 具有偏向选择性。PRT2527 旨在成为一种强效且选择性的 CDK9 抑制剂。其 MCL1 候选药物 PRT1419 旨在成为抗凋亡蛋白 MCL1 的强效选择性抑制剂。
公司简介
公司代码PRLD
公司名称Prelude Therapeutics Inc
上市日期Sep 25, 2020
CEODr. Krishna (Kris) Vaddi, Ph.D.
员工数量131
证券类型Ordinary Share
年结日Sep 25
公司地址175 Innovation Boulevard
城市WILMINGTON
上市交易所NASDAQ Global Select Consolidated
国家United States of America
邮编19805
电话13024671280
网址https://preludetx.com/
公司代码PRLD
上市日期Sep 25, 2020
CEODr. Krishna (Kris) Vaddi, Ph.D.
公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Krishna (Kris) Vaddi, Ph.D.
Dr. Krishna (Kris) Vaddi, Ph.D.
Chief Executive Officer, Founder, Director
Chief Executive Officer, Founder, Director
3.67M
+29.33%
Dr. Paul A. Friedman, M.D.
Dr. Paul A. Friedman, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
500.10K
--
Dr. Andrew P. Combs, Ph.D.
Dr. Andrew P. Combs, Ph.D.
Chief Chemistry Officer
Chief Chemistry Officer
480.12K
+27.99%
Dr. Peggy A. Scherle, Ph.D.
Dr. Peggy A. Scherle, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
185.69K
+2.77%
Dr. Jane Huang, M.D.
Dr. Jane Huang, M.D.
President, Chief Medical Officer
President, Chief Medical Officer
90.27K
+7.15%
Ms. Mardi C. Dier
Ms. Mardi C. Dier
Independent Director
Independent Director
10.00K
--
Dr. Paul Scherer, M.D.
Dr. Paul Scherer, M.D.
Independent Director
Independent Director
--
--
Dr. Victor Sandor, M.D.
Dr. Victor Sandor, M.D.
Independent Director
Independent Director
--
--
Mr. Bryant D. Lim, J.D.
Mr. Bryant D. Lim, J.D.
Chief Financial Officer, Chief Legal Officer, Corporate Secretary
Chief Financial Officer, Chief Legal Officer, Corporate Secretary
--
--
Dr. David P. Bonita, M.D.
Dr. David P. Bonita, M.D.
Independent Director
Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Krishna (Kris) Vaddi, Ph.D.
Dr. Krishna (Kris) Vaddi, Ph.D.
Chief Executive Officer, Founder, Director
Chief Executive Officer, Founder, Director
3.67M
+29.33%
Dr. Paul A. Friedman, M.D.
Dr. Paul A. Friedman, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
500.10K
--
Dr. Andrew P. Combs, Ph.D.
Dr. Andrew P. Combs, Ph.D.
Chief Chemistry Officer
Chief Chemistry Officer
480.12K
+27.99%
Dr. Peggy A. Scherle, Ph.D.
Dr. Peggy A. Scherle, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
185.69K
+2.77%
Dr. Jane Huang, M.D.
Dr. Jane Huang, M.D.
President, Chief Medical Officer
President, Chief Medical Officer
90.27K
+7.15%
Ms. Mardi C. Dier
Ms. Mardi C. Dier
Independent Director
Independent Director
10.00K
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 7月27日 周日
更新时间: 7月27日 周日
持股股东
股东类型
持股股东
持股股东
占比
OrbiMed Advisors, LLC
25.02%
Baker Bros. Advisors LP
23.20%
Vaddi (Krishna)
8.41%
Boxer Capital Management, LLC
4.83%
The Vanguard Group, Inc.
2.31%
Other
36.22%
持股股东
持股股东
占比
OrbiMed Advisors, LLC
25.02%
Baker Bros. Advisors LP
23.20%
Vaddi (Krishna)
8.41%
Boxer Capital Management, LLC
4.83%
The Vanguard Group, Inc.
2.31%
Other
36.22%
股东类型
持股股东
占比
Hedge Fund
31.09%
Private Equity
25.02%
Individual Investor
11.38%
Investment Advisor
9.38%
Investment Advisor/Hedge Fund
3.57%
Research Firm
0.70%
Venture Capital
0.06%
Bank and Trust
0.04%
Pension Fund
0.01%
Other
18.77%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
158
35.42M
81.22%
-13.38M
2025Q1
169
35.41M
81.20%
-13.64M
2024Q4
176
41.97M
99.49%
-4.74M
2024Q3
176
39.67M
94.09%
-11.21M
2024Q2
173
43.50M
103.37%
-2.47M
2024Q1
184
38.12M
90.60%
-8.41M
2023Q4
190
38.61M
71.39%
-9.45M
2023Q3
202
40.53M
76.60%
-4.90M
2023Q2
201
43.54M
105.11%
+2.58M
2023Q1
203
37.45M
102.57%
-2.14M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
OrbiMed Advisors, LLC
10.91M
25.02%
--
--
Mar 31, 2025
Baker Bros. Advisors LP
10.12M
23.2%
-5.19K
-0.05%
Jun 12, 2025
Vaddi (Krishna)
3.67M
8.41%
+832.02K
+29.33%
Mar 31, 2025
Boxer Capital Management, LLC
2.11M
4.83%
+399.83K
+23.41%
Mar 31, 2025
The Vanguard Group, Inc.
1.01M
2.31%
-1.19K
-0.12%
Mar 31, 2025
T. Rowe Price Associates, Inc.
959.30K
2.2%
-53.05K
-5.24%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
919.00K
2.11%
-14.36K
-1.54%
Mar 31, 2025
Renaissance Technologies LLC
656.70K
1.51%
+22.20K
+3.50%
Mar 31, 2025
Acadian Asset Management LLC
529.33K
1.21%
+43.95K
+9.05%
Mar 31, 2025
Friedman (Paul A)
500.10K
1.15%
--
--
Mar 31, 2025
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
Dimensional US Core Equity 1 ETF
0%
iShares Russell 2000 ETF
0%
Proshares Ultra Russell 2000
0%
ProShares UltraPro Russell2000
0%
ProShares Ultra Nasdaq Biotechnology
0%
Schwab U.S. Small-Cap ETF
0%
Schwab U.S. Broad Market ETF
0%
iShares Micro-Cap ETF
0%
Invesco Nasdaq Biotechnology ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
0%
查看更多
Dimensional US Core Equity 1 ETF
占比0%
iShares Russell 2000 ETF
占比0%
Proshares Ultra Russell 2000
占比0%
ProShares UltraPro Russell2000
占比0%
ProShares Ultra Nasdaq Biotechnology
占比0%
Schwab U.S. Small-Cap ETF
占比0%
Schwab U.S. Broad Market ETF
占比0%
iShares Micro-Cap ETF
占比0%
Invesco Nasdaq Biotechnology ETF
占比0%
iShares Core S&P Total U.S. Stock Market ETF
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
